Dat	.e:2022/11/	Z8	
	ır Name: Yijie I		
Ма	nuscript Title: Apatinib	in the treatment of gastric	cancer in Henan Province: a multicenter real-world
	erience (Ahead-HAP01)		
-	nuscript number (if known):		
relapar to to trela The ma	ated to the content of your raties whose interests may be ransparency and does not nationship/activity/interest, it following questions apply tauscript only.	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. t is preferable that you do to the author's relationship vities/interests should be on nsion, you should declare	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive
	tem #1 below, report all sup time frame for disclosure is	-	in this manuscript without time limit. For all other iten
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initia	planning of the work
1	All support for the present	X None	
_	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
		1	
	processing charges, etc.)		
	processing charges, etc.) No time limit for this item.		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.	Time frame: pas	t 36 months
2	No time limit for this item. Grants or contracts from	Time frame: pas	t 36 months
2	No time limit for this item. Grants or contracts from any entity (if not indicated		t 36 months
	No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).		t 36 months
2	No time limit for this item. Grants or contracts from any entity (if not indicated		t 36 months
	No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	XNone	t 36 months
	No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	XNone	t 36 months

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Jate	e:2022/11/	28	
ou!	r Name: Weijie	e Zhao	
Mar	uscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world
хре	erience (Ahead-HAP01)		
/lar	uscript number (if known):		
ela part o tr ela	ted to the content of your n ies whose interests may be ansparency and does not n tionship/activity/interest, it	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current
	uscript only.	o the author's relationship	by activities/interests as they relate to the <u>current</u>
ned n it	lication, even if that medica	ntion is not mentioned in to	all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other iten
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate none (add rows as needed)	institution)
		Time frame: Since the initia	al planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
	Cuente en equitire de forme	Time frame: pas	t 36 months
	Grants or contracts from any entity (if not indicated	XNone	
	any chary in not malcated		
	in item #1 above).		
	in item #1 above). Royalties or licenses	X None	
,	in item #1 above). Royalties or licenses	XNone	
3	•	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Dat	te:2022/11/	28	
Υοι	ır Name: Peich	un Sun	
Ma	nuscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world
-	erience (Ahead-HAP01)		
Ma	nuscript number (if known):		
rela par to t	ated to the content of your rities whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
		o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
<u>ma</u>	nuscript only.		
me In i	dication, even if that medica	ntion is not mentioned in to	all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other iter
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting for	V. Nasa	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Dat	:e:2022/11/	28	
Υοι	ır Name: Weny	ring Deng	
Ma	nuscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world
-	erience (Ahead-HAP01)		
Ma	nuscript number (if known):		
rela par to t	ated to the content of your r ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
		o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
ma	nuscript only.		
me In i	dication, even if that medica	ntion is not mentioned in to	all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other item
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X None	
	7 3.1.1.2.2.2.1.1.00.1.000		
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

υaι	e:zuzz/11/	28	
You	ır Name: Junli I	Deng	
Mai	nuscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world
	erience (Ahead-HAP01)		
-	nuscript number (if known):		
rela part to t rela The	ited to the content of your name ites whose interests may be ransparency and does not not items.	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current
to t med In it	he epidemiology of hyperte dication, even if that medica tem #1 below, report all sup	nsion, you should declare ation is not mentioned in to port for the work reported	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other iten
tne	time frame for disclosure is	the past 36 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initia	al planning of the work
	T		al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	et 26 months
ว	Crants or contrasts from		it 30 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Dai	.e:2022/11/	28	
Υοι	ır Name: Hong	Zong	
Ma	nuscript Title: Apatinib	in the treatment of gastric	c cancer in Henan Province: a multicenter real-world
	perience (Ahead-HAP01)		
-	nuscript number (if known):		
rela par to t rela	ated to the content of your nation whose interests may be ransparency and does not nationship/activity/interest, in	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment of the manuscript of the manuscript. Disclosure represents a commitment of the manuscript. Discl
to t me In i	the epidemiology of hyperte dication, even if that medica	nsion, you should declare ation is not mentioned in to port for the work reported	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive he manuscript. I in this manuscript without time limit. For all other iten
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
	Davidia andia		
3	Royalties or licenses	XNone	
	Royalties or licenses	XNone	
	Royalties or licenses	XNone	
	Consulting fees	XNoneXNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Date:2022/11,	/28	
Your Name: Junsh	neng Wang	
Manuscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world
experience (Ahead-HAP01)		
Manuscript number (if known)	<u> </u>	
related to the content of your reparties whose interests may be to transparency and does not no relationship/activity/interest, in the following questions apply the manuscript only. The author's relationships/activity to the epidemiology of hypertemedication, even if that medications are provided in the medication.	manuscript. "Related" means affected by the content of the author's relationship of the author's relationship of the content o	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
	needed)	
	Time frame: Since the initial	al planning of the work
All support for the present	XNone	
manuscript (e.g., funding,		
provision of study materials, medical writing, article		
processing charges, etc.)		
No time limit for this item.		
The same in the state of the st		
	Time frame: pas	at 26 months
2 Grants or contracts from	X None	oc 30 mondis
any entity (if not indicated		
in item #1 above).		
Royalties or licenses	X None	
Noyalties of ficerises		
4 Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Dat	e:2022/11/	28	
Υου	ır Name: Yanzh	nen Guo	
Ma	nuscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world
-	erience (Ahead-HAP01)		
Ma	nuscript number (if known):		
rela par to t	ited to the content of your r ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	• • • • • • • • • • • • • • • • • • • •	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
ma	nuscript only.		
me In it	dication, even if that medica	ntion is not mentioned in to	all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other iten
		Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
	No time inime for this item.		
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X None	
J	No yaities of neclises		
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Date	e:2022/11/	['] 28	
You	Name: Huain	nin Liu	
Man	uscript Title: Apatinib	in the treatment of gastric	cancer in Henan Province: a multicenter real-world
•	erience (Ahead-HAP01)		
Man	uscript number (if known):		
relat part to tr relat	ted to the content of your name ies whose interests may be ansparency and does not not ionship/activity/interest, it following questions apply to	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of the graph of the second of the
man	uscript only.		
to th med In ite	ne epidemiology of hyperte ication, even if that medica	nsion, you should declare a stion is not mentioned in the port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. I in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	26 months
2	Grants or contracts from	X None	. So months
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	XNone	
	o lu t	V 1	
4	Consulting fees	X None	1

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Date	e:2022/11/	28	
You	Name: Shund	dong Cang	
			c cancer in Henan Province: a multicenter real-world
ехре	erience (Ahead-HAP01)		
Man	uscript number (if known):		
related to the control of the contro	tied to the content of your names ies whose interests may be an sparency and does not not ionship/activity/interest, it following questions apply tous cript only. author's relationships/activity endemiology of hyperte ication, even if that medical	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do o the author's relationship vities/interests should be nsion, you should declare ation is not mentioned in t	os/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertain all relationships with manufacturers of antihypertensive
	time frame for disclosure is	•	·
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
L	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
-	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
1	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Dat	e:zuzz/11/	28	
	r Name:Ke Sha		
Maı	nuscript Title: Apatinib	in the treatment of gastric	cancer in Henan Province: a multicenter real-world
	erience (Ahead-HAP01)		
-	nuscript number (if known):		
	•		
relacion trelacion trelaci	ted to the content of your name ies whose interests may be ransparency and does not not interest, it following questions apply the content only.	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so to the author's relationship wities/interests should be <u>donion, you should declare</u> a	es/activities/interests as they relate to the <u>current</u> <u>lefined broadly</u> . For example, if your manuscript pertain all relationships with manufacturers of antihypertensive
	em #1 below, report all sup time frame for disclosure is		in this manuscript without time limit. For all other iten
		Nome all autities with	Specifications/Comments
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	institution
		needed)	
		Time frame: Since the initia	I planning of the work
	All support for the green		pariting of the work
1	All support for the present	XNone	
	manuscript (e.g., funding, provision of study materials,		
		<u> </u>	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
<u> </u>	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

υaι	e:2022/11/	28	
Υοι	ır Name: Xiaob	ing Chen	
Ма	nuscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world
	erience (Ahead-HAP01)		
-	nuscript number (if known):		
	nasenpe namber (ii known).		
rela par to t rela	ited to the content of your raties whose interests may be ransparency and does not nationship/activity/interest, it following questions apply to	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current
ma	nuscript only.		
In it	dication, even if that medicatem #1 below, report all suptime frame for disclosure is	port for the work reported	he manuscript. d in this manuscript without time limit. For all other iten
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Dai	.e:2022/11/	28	
Υοι	ur Name: Jin Wa	ang	
			c cancer in Henan Province: a multicenter real-world
	perience (Ahead-HAP01)		
-	nuscript number (if known):		
rela par to t	ated to the content of your nations whose interests may be transparency and does not not not to the state of	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a
rela	ationship/activity/interest, it	is preferable that you do	so.
	e following questions apply t nuscript only.	o the author's relationship	ps/activities/interests as they relate to the <u>current</u>
to t		nsion, you should declare	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.
	time frame for disclosure is	- -	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X None	
J	no yanties of necrises		
4	Consulting fees	X None	
	1		

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None		

Dat	:e:2022/11/	28	
Υοι	ır Name: Dezhi	He	
Ma	nuscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world
-	erience (Ahead-HAP01)		
Ma	nuscript number (if known):		
rela par to t rela	ated to the content of your nation whose interests may be transparency and does not nationship/activity/interest, in	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do	
		o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
<u>ma</u>	nuscript only.		
me In i	dication, even if that medica	ntion is not mentioned in to	all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other iten
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None		

Dai	le:2022/11/	28	
Υοι	ur Name: Gang	Wu	
Ма	nuscript Title: Apatinib	in the treatment of gastric	c cancer in Henan Province: a multicenter real-world
	perience (Ahead-HAP01)		
-	nuscript number (if known):		
	, , ,		
rela par to t rela The ma	eted to the content of your nations whose interests may be transparency and does not not interest, in the following questions apply to the content only. The author's relationships/activities apply the content only.	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do to the author's relationship vities/interests should be on nsion, you should declare	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertain all relationships with manufacturers of antihypertensive
ne	dication, even if that medica	ation is not mentioned in t	he manuscript.
		· ·	d in this manuscript without time limit. For all other iten
the	time frame for disclosure is	the past 36 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
	No time minit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	
,	Janeico di necrioco		
4	Consulting fees	X None	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None		

Dat	e:zuzz/11/	28	
	r Name: Zhen :		
			cancer in Henan Province: a multicenter real-world
	erience (Ahead-HAP01)		
-	nuscript number (if known):		
rela part to t rela The mar	ted to the content of your naties whose interests may be ransparency and does not nationship/activity/interest, it following questions apply thuscript only.	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. t is preferable that you do o the author's relationship vities/interests should be <u>c</u> nsion, you should declare a	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive
	em #1 below, report all sup time frame for disclosure is	•	I in this manuscript without time limit. For all other iten
		A1 11 1212 211	
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as	institution)
		needed)	
		Time frame: Since the initia	I planning of the work
			n planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	I		
	in item #1 above).		
3	Royalties or licenses	XNone	
3	·	XNone	
3	·	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None		

Dat	e:zuzz/11/	28	
Υοι	r Name: Liguo	Zhang	
Ма	nuscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world
	erience (Ahead-HAP01)		
-	nuscript number (if known):		
rela par to t rela	ited to the content of your naties whose interests may be ransparency and does not notionship/activity/interest, it	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so. ps/activities/interests as they relate to the current
ma	nuscript only.		
me In i	dication, even if that medica	tion is not mentioned in t	all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other iten
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	·
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	X None	
-	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	X None	
_	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	
	noyalties of neerises		
4	Consulting fees	X None	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None		

)at					
ou/	ır Name: Feng	Xu			
Мa	nuscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world		
хp	erience (Ahead-HAP01)				
/la	nuscript number (if known):				
ela ar o t ela	ated to the content of your raties whose interests may be ransparency and does not nationship/activity/interest, i	manuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current		
	nuscript only.	to the author's relationship	os/activities/interests as they relate to the <u>current</u>		
neo n it	dication, even if that medica	etion is not mentioned in to	all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other iten		
Name all entities with Specifications/Comments					
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)		
		none (add rows as			
		needed)			
	All support for the present manuscript (e.g., funding,	-			
	manuscript (e.g., funding, provision of study materials,	needed) Time frame: Since the initi			
•	manuscript (e.g., funding, provision of study materials, medical writing, article	needed) Time frame: Since the initi			
•	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	needed) Time frame: Since the initi			
	manuscript (e.g., funding, provision of study materials, medical writing, article	needed) Time frame: Since the initi			
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	needed) Time frame: Since the initi			
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	needed) Time frame: Since the initionXNone	al planning of the work		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	needed) Time frame: Since the initi	al planning of the work		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	needed) Time frame: Since the initionXNone Time frame: pas	al planning of the work		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	needed) Time frame: Since the initionXNone Time frame: pas	al planning of the work		
L 2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	needed) Time frame: Since the initionXNone Time frame: pas	al planning of the work		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	needed) Time frame: Since the initionXNone	al planning of the work		
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	needed) Time frame: Since the initionXNone	al planning of the work		

5	Payment or honoraria for lectures, presentations,	XNone			
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Cuppert for attending	V None			
,	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
10	D				
12	Receipt of equipment,	XNone			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None			

Dat	:e:2022/11/	/28	
Υου	ır Name: Chun	tao Tian	
Ma	nuscript Title: Apatinib	in the treatment of gastri	ic cancer in Henan Province: a multicenter real-world
ехр	erience (Ahead-HAP01)		
Ma	nuscript number (if known):		
rela par to t rela	ated to the content of your raties whose interests may be transparency and does not nationship/activity/interest, it following questions apply to	manuscript. "Related" mea affected by the content of eccessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a o so. ps/activities/interests as they relate to the current
ma	nuscript only.		
me In it	dication, even if that medica	pport for the work reporte	all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other iten
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present		ar planning of the work
Т	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time from each	ct 26 months
2	Grants or contracts from	Time frame: pas X None	St 30 months
_	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
1	Conculting for	V None	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None		

Dat	e:2022/11/	28	
You	r Name: Chaof	eng Qiao	
Maı	nuscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world
-	erience (Ahead-HAP01)		
Maı	nuscript number (if known):		
rela part to t	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.
	following questions apply touscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to t med In it	he epidemiology of hyperte dication, even if that medica	nsion, you should declare ation is not mentioned in to port for the work reported	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other iter
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None		

Dat	:e:2022/11/	/28	
Υοι	ır Name: Gong	bin Chen	
Ma	nuscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world
-	erience (Ahead-HAP01)		
Ma	nuscript number (if known):		
rela par to t	ated to the content of your r ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
		to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
<u>ma</u>	nuscript only.		
me In i	dication, even if that medica	nation is not mentioned in to	all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other item
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
	,		
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None		

Dat	e:2022/11/	28	
	r Name: Guifa		
Maı	nuscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world
-	erience (Ahead-HAP01)		
Maı	nuscript number (if known):		
rela pari to t	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to t med In it	he epidemiology of hyperte dication, even if that medica	nsion, you should declare ation is not mentioned in to port for the work reported	<u>defined broadly</u> . For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other iter
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
	· 	Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus, manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role	X None			
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None		

Date:2022	<u> </u>	
our Name:1	ianjiang Ma	
Manuscript Title: Apa	tinib in the treatment of gastri	ic cancer in Henan Province: a multicenter real-world
experience (Ahead-HAP01)		
/lanuscript number (if kno	wn):	
elated to the content of y parties whose interests ma o transparency and does i elationship/activity/inter	our manuscript. "Related" mean ay be affected by the content of not necessarily indicate a bias. est, it is preferable that you do	
ne rollowing questions ap <u>nanuscript only</u> .	ply to the author's relationshi	ips/activities/interests as they relate to the current
nedication, even if that m	edication is not mentioned in t	e all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other iten
	Name all entities with	Specifications/Comments
	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
	Time frame: Since the initi	ial planning of the work
All support for the prese manuscript (e.g., fundin provision of study mater medical writing, article processing charges, etc. No time limit for this ite	g, rials,	
Countries	Time frame: pas	st 36 months
Grants or contracts from any entity (if not indicat		
in item #1 above).	eu	+
Royalties or licenses	X None	
Noyunics of ficerises	XNONE	
Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Date	e:2022/11/	⁷ 28	
	Name:Liwei		
Man	uscript Title: Apatinib	in the treatment of gastri	c cancer in Henan Province: a multicenter real-world
ехре	erience (Ahead-HAP01)		
Man	uscript number (if known):		
relat part to tr relat	eed to the content of your name ies whose interests may be ansparency and does not not ionship/activity/interest, it following questions apply to	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current
man	uscript only.		
med In ite	ication, even if that medica	ntion is not mentioned in to	all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other item
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		-:	25
2	Crants or contracts from	Time frame: pas	at 36 months
2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	X None	
5	noyalties of ficelises		
4	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Dat	.e:2022/11/	28	
	ır Name:Guozh		
Ма	nuscript Title: Apatinib	in the treatment of gastric	c cancer in Henan Province: a multicenter real-world
	erience (Ahead-HAP01)		
-	nuscript number (if known):		
relato trela	ated to the content of your raties whose interests may be ransparency and does not nationship/activity/interest, in	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current
o t ne	he epidemiology of hyperte dication, even if that medica	nsion, you should declare a ation is not mentioned in the	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. I in this manuscript without time limit. For all other item
he	time frame for disclosure is	the past 36 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present		6
_	All support for the present	Y None	
	1	XNone	
	manuscript (e.g., funding,	XNone	
	manuscript (e.g., funding, provision of study materials,	XNone	
	manuscript (e.g., funding, provision of study materials, medical writing, article	XNone	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	XNone	
	manuscript (e.g., funding, provision of study materials, medical writing, article	XNone	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	XNone	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: pas	t 36 months
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from		t 36 months
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Time frame: pas	t 36 months
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pas	t 36 months
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Time frame: pas	t 36 months
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pass	t 36 months
2 3	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pass	t 36 months

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Date	:2022/11/	28	
Your	Name: Jing Li	iu	
Man	uscript Title: Apatinib	in the treatment of gastric	cancer in Henan Province: a multicenter real-world
	rience (Ahead-HAP01)		
Man	uscript number (if known):		
relat parti to tra relat The a man The a to th medi	ted to the content of your name ies whose interests may be ansparency and does not not ionship/activity/interest, infollowing questions apply tous apply tous and tou	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do to the author's relationship wities/interests should be dension, you should declare a tion is not mentioned in the	es/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None		

Date:28/11/2022
Your Name:_Guy Eslick
Manuscript Title: Apatinib in the treatment of gastric cancer in Henan Province: a multicenter real-world
experience (Ahead-HAP01)
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony	XNone	
	,		
7	Support for attending meetings and/or travel	XNone	
	g ,		
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

Please summarize the above conflict of interest in the following box:

None		

Please place an "X" next to the following statement to indicate your agreement:

Date:28-november-2022	
Your Name:Khaldoun Almhanna	
Manuscript Title: $_$ $\mathbf A$ $\mathbf p$ $\mathbf a$ $\mathbf t$ $\mathbf n$ $\mathbf m$ \mathbf	multicenter real-world
experience (Ahead-HAP01)	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

	T	·	
5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
U	testimony	XNOTIE	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel	<u></u>	
	, , , , , , , , , , , , , , , , , , ,		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the fo	ollowing box:

_X I certify that I have answered every question and have not altered the wording of any of the control form.	Juestions on this

Date:_November 25 th	, 2022
Your Name:Leona	rdo S. Lino-Silva
Manuscript Title:	Apatinib in the treatment of gastric cancer in Henan Province: a multicenter real-world
<u>experience (Ahead-H</u>	<u>AP01)</u>
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:

None conflict of interest to declare.

Date:Nov 24 2022
our Name: Giuseppe Aprile
Manuscript Title: Apatinib in the treatment of gastric cancer in Henan Province: a multicenter real-world experience
Ahead-HAP01)
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
O	testimony	None	
	testimony		
7	Support for attending	None	
•	meetings and/or travel		
	G ,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data		Advisory board for Astellas, Astra Zeneca, Sanofi, BMD,
	Safety Monitoring Board or		MSD
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Please summarize the above conflict of interest in the following box:

Participation to Advisory board for Astellas, Astra Zeneca, Sanofi, BMD, MSD.

Date	e:2022/11/	[/] 28				
You	r Name: Ning I	Li				
Man	Manuscript Title: Apatinib in the treatment of gastric cancer in Henan Province: a multicenter real-world					
ехре	erience (Ahead-HAP01)					
Man	uscript number (if known):					
relate part to trelate The man The to the med	ted to the content of your name ies whose interests may be cansparency and does not not ionship/activity/interest, in following questions apply touscript only. author's relationships/activity endemiology of hypertedication, even if that medications is some content of the con	manuscript. "Related" mea affected by the content of ecessarily indicate a bias. It is preferable that you do to the author's relationship wities/interests should be on nsion, you should declare a ation is not mentioned in the	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive			
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)			
		needed)				
		Time frame: Since the initia	l planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone				
		Time frame: past	t 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone				
3	Royalties or licenses	XNone				
4	Consulting fees	XNone				

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus, manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary role	X None		
10	in other board, society,	XNone		
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			

None		

Date:	2022/11/2	28	
		uo	
Manuscri	pt Title: Apatinib i	n the treatment of gastric	cancer in Henan Province: a multicenter real-world
experienc	ce (Ahead-HAP01)		
Manuscri	ipt number (if known):_		
related to parties w to transprelationsl The follow manuscri	the content of your methose interests may be arency and does not nethin hip/activity/interest, it wing questions apply to pt only.	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do the author's relationship	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current defined broadly. For example, if your manuscript pertains
medication	on, even if that medica	tion is not mentioned in the	all relationships with manufacturers of antihypertensive ne manuscript. I in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
man prov med proc	upport for the present uscript (e.g., funding, ision of study materials, ical writing, article essing charges, etc.) ime limit for this item.	XNone	
		Time frame: past	236 months
any e	nts or contracts from entity (if not indicated em #1 above).	XNone	
3 Roya	alties or licenses	XNone	
4 Cons	sulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Please summarize the above conflict of interest in the following box:			

None		